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Abstract 
Background: Plasmodium vivax accounts for about 44 % of all malaria infection in Ethiopia. Chloroquine (CQ) is the 
first-line treatment for vivax malaria in Ethiopia. Chloroquine-resistant (CQR) P. vivax has been emerging in differ-
ent parts of the world to compromise the efficacy of the drug and pose both health and economic impact in the 
developing world. The current study was aimed at assessing the therapeutic efficacy of CQ for the treatment of vivax 
malaria among outpatients at Hossana Health Care Centre, southern Ethiopia.
Methods: A one-arm, 28-day follow-up, in vivo therapeutic efficacy study was conducted from 5 April to 25 June, 
2014. Sixty-three patients aged between four and 59 years were enrolled with microscopically confirmed P. vivax 
infection. All patients were treated with CQ 25 mg/kg for 3 days. Recurrence of parasitaemia and clinical conditions of 
patients were assessed on days 1, 2, 3, 7, 14, 21, and 28 during the 28-day follow-up period. Haemoglobin (Hb) level 
was determined on day 0, day 28 and on day of recurrence of parasitaemia by using portable spectrophotometer.
Results: Of the total 63 patients included in the study, 60 (95.2 %) completed their 28-day follow-up; three patients 
were excluded from the study: one patient due to vomiting of the second dose of drug, one patient due to Plasmo-
dium falciparum infection and one patient lost to follow-up during the study. During enrolment, 35 (53.3 %) had a his-
tory of fever and 28 (46.7 %) had documented fever. The geometric mean of parasite density on day of enrolment was 
3472 parasites/μl. Among these, two patients had recurrent parasitaemia within the 28-day follow-up. CQ was found 
to be efficacious in 96.7 % of the study participants except two treatment failures detected. The failure might be due 
to late parasitological failure among these two patients who had recurrent parasitaemia within the 28-day follow-up.
Conclusion: The current study revealed that CQ showed a high rate of efficacy (96.7 %) among the study participants 
even though some reports from previous studies elsewhere in Ethiopia showed an increase in CQR P. vivax. Thus, CQR 
molecular markers and regular monitoring of the pattern of resistance to CQ is needed for rapid and effective control 
measures of possible spread of drug resistance in the study area.
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Background
Malaria is a major public health problem and causes 
much suffering and premature death in tropical Africa, 
Asia and Latin America and occurs in 110 countries with 
about 40 % of the world’s population at risk [1]. Approxi-
mately 52 million people live in malaria-risk areas in 
Ethiopia, with mainly seasonal, unstable transmission in 
the highlands and longer transmission duration in low-
land areas, river basins and valleys [2].
The emergence and rapid spread of resistant para-
sites to anti-malarial drugs, and vectors to insecticides, 
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respectively, has worsened the problem of control [3]. 
Chloroquine (CQ) is the cheapest anti-malarial drug 
available at peripheral level (sub-health post and health 
post without laboratory facilities). It is used for treatment 
of laboratory-confirmed Plasmodium vivax and sympto-
matic malaria [4]. However, some studies revealed that 
the emergence of chloraquine-resistant (CQR) strains of 
P. vivax has been alarming and affected endemic coun-
tries, such as Ethiopia [5–8], Madagascar [9], Myan-
mar [10], and Indonesia [11]. High levels of CQR on the 
northern part of the islands of New Guinea and Sumatra, 
Indonesia have been well documented, as well as spo-
radic reports from other locations [12].
The World Health Organization (WHO) recommended 
that drug efficacy be regularly assessed. Failure to detect 
the emergence of anti-malarial drug resistance could lead 
to a drug-resistant malaria epidemic which would have 
major public health and economic consequences for an 
area, province and country [3, 13, 14]. Therefore, moni-
toring of drug resistance is essential for timely changes 
to treatment policy, which should be initiated when the 
treatment failure rate exceeds 10 % at the end of follow-
up [13]. However, a decision to change treatment policy 
may be influenced by a number of additional factors, 
including the prevalence and geographical distribution of 
reported treatment failures, health service provider and/
or patient dissatisfaction with the treatment, the political 
and economic context, and the availability of affordable 
alternatives to the commonly used treatment [15].
Emergence and the spread of CQR P. vivax  strains is 
becoming a major public health problem in different 
countries, and requires regular monitoring to control 
its spread [1]. There are a few reports of CQR P. vivax in 
different parts of Ethiopia [6–8]. Such evidence neces-
sitates a need for urgent assessment to obtain informa-
tion in order to develop or change treatment policies [3, 
13]. This study was conducted to assess the therapeutic 
efficacy of CQ for the treatment of vivax malaria among 




The study was conducted in Hadiya Zone, Hossana Town, 
which is located in the Ethiopian Rift Valley (Fig.  1), in 
the north-western part of Southern Nation’s Nation-
alities and Peoples’ Region (SNNPR), 230  km south of 
Addis Ababa and 145 km from Hawassa. The town lies at 
a longitude of 10°060 N 39°590 E and latitude of 10.1°N 
39.983° E. The town has a total of 104,208 inhabitants. 
The area has a short rainy season from March to May and 
a high rainfall during the main season (June–September) 
and is characterized by unstable and seasonal malaria, 
one of the main diseases in the town and its surround-
ings, that occurs with peak transmission following the 
rainy seasons [17].
The study participants were patients with confirmed P. 
vivax mono-infection on thick and thin blood film prepa-
rations and who fulfilled the inclusion criteria [13] and 
were seeking treatment at Hossana Health Centre during 
the study period. The source population were those clini-
cally malaria-suspected individuals with fever or history 
of fever seeking treatment at Hossana Health Care Cen-
tre during the study period.
The inclusion criteria included age over 6  months, 
mono-infection with P. vivax detected by micros-
copy, asexual parasite count  >250/μl, axillary tempera-
ture  ≥37.5  °C or history of fever during the previous 
48  h, ability to swallow oral medication, willingness 
to comply with the study for the duration of the study, 
informed consent from the patient or parent/guardian 
in the case of children [3, 13]. Participants who were 
infected with vivax malaria requiring hospitalization, 
or had severe malnutrition, febrile condition due to 
diseases other than malaria, regular medication which 
might interfere with anti-malarial pharmacokinetics, 
were pregnant and breastfeeding, were excluded from 
the study [3, 13].
The required sample size was calculated based on the 
prevalence of 3.6  % treatment failure in a study con-
ducted in Serbo Town [7], 5 % precision, 95 % confidence 
level. An additional 20 % (10 patients) were expected loss 
to follow-up rate and withdrawal of consent during the 
study, and therefore 63 participants were included.
Study design
A one-arm, prospective evaluation of clinical and para-
sitological responses to directly observed treatment for 
vivax malaria was used. Patients with P. vivax infection, 
who fulfilled the inclusion criteria were enrolled, treated 
and followed for 28 days. The follow-up included a fixed 
schedule (1, 2, 3, 7, 14, 21, and 28 days) of check-up visits 
and corresponding clinical and laboratory examinations 
[13].
Questionnaires were used to gather general informa-
tion such as socio-demographic information from study 
participants by senior laboratory technologists and 
checked by the principal investigator for completeness. 
Clinical and laboratory information were collected as 
follows:
Treatment and follow‑up
A 28-day, in vivo, drug efficacy testing was done accord-
ing to methods recommended by WHO [16] and the 
Ethiopian Ministry of Health [17]. Patients were treated 
with a 25  mg/kg CQ-sulfate (Addis Pharmaceuticals, 
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Adigrat, batch number 9461, date 02/2011 and expira-
tion 02/2016), administered for three consecutive days 
(10, 10 and 5 mg/kg on days 0, 1 and 2, respectively) [4, 
18, 19] at Hossana Health Care Centre. All doses were 
administered under direct observation. Study subjects 
were checked for vomiting for 30 min after intake of the 
drug; those who vomited were retreated with the same 
dose. Subjects who vomited twice were excluded from 
the study. The study participants were advised not to take 
other drugs, except for patients with axillary tempera-
ture >37.5 °C who were treated with paracetamol (10 mg/
kg). Patients were advised to come back to the Health 
Care Centre if they felt sick at any time during the follow-
up period for clinical and parasitological examination. In 
particular, parents or guardians were instructed to bring 
children to the Health Care Centre at any time if they 
showed any sign of danger (unable to drink or breast-
feed, vomiting, presenting with convulsions, lethargic or 
unconscious, unable to sit or stand, presenting with dif-
ficult breathing) [13].
Patients who met all the inclusion criteria were given 
a personal identification number and received treatment 
only after the study was fully explained and informed 
consent provided. Patients who decided to participate in 
the study were examined, treated and followed. Succes-
sive monitoring of parasitological and clinical responses 
was made on the follow-up days to each patient until 
day 28. The day a patient was enrolled and received the 
first dose of CQ was designated as day 0. Patients were 
informed to come for follow-up on days 1, 2, 3, 7, 14, 21, 
and 28. Thick and thin blood smears were prepared and 
examined for checking parasite clearance and/or recur-
rence of parasitaemia at all follow-up visits. Haemoglo-
bin measurement was made on days 0 and 28 during 
follow-up and on day of recurrence of parasitaemia. Any 
patient who did not come to the Health Care Centre on 
the day of appointment was traced at his/her home and 
assisted by the health extension workers to complete the 
follow-up.
Clinical procedures
Physical examinations such as the auxiliary tempera-
ture, weight and clinical conditions were done during the 
study period for all study participants.
Fig. 1 Map of the study area
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Laboratory procedures
Capillary blood was collected from each study partici-
pant; duplicate thick and thin blood films were made 
at recruitment and on each follow-up days. The blood 
films were stained with stained with 10  % Giemsa for 
10  min, examined with100X oil immersion objective. 
Species identification and parasite quantification was 
done by trained senior medical laboratory technologist 
and reports were recorded on the laboratory request. 
The thick blood smears were used to count the num-
bers of asexual parasites and white blood cells (WBCs) 
in a limited number of microscopic fields. Plasmodium 
vivax asexual stages were counted against 200 WBCs. 
Parasitaemia was determined according to formula 
below [13].
Haemoglobin was measured on days 0 and 28 during 
follow-up for each study participants and on day of recur-
rence of parasitaemia. Finger-pricked blood was taken 
and read by portable spectrophotometer (HemoCue Hb 
301 System, Sweden). Anaemia was defined according to 
[20] categorization.
Urine of all female participants was screened for preg-
nancy by Strip Test, (PR China, date 2012/11, Expiration 
2014/11, Batch number W00121125.2) and those testing 
positive were excluded from the study.
Study endpoints
Study participants were classified either as ‘adequate clin-
ical and parasitological responses’, in the absence of para-
site recurrence within 28 days of follow-up, or ‘treatment 
failure’ in case of recurrence of parasitaemia during fol-
low-up and new infection with Plasmodium falciparum 
(within 28 days).
Statistical analysis
Statistical Package for Social Science (SPSS) version 
16 was used for data management and analysis. Data of 
patients having mixed infection with P. falciparum, lost 
to follow-up and vomiting were excluded from the analy-
sis according to WHO method. The analysis included the 
proportion of early treatment failure (ETF), late clini-
cal failure (LCF), late parasitological failure (LPF), and 
adequate clinical and parasitological response (ACPR) 
at day 28. Kaplan–Meier survival estimate was used to 
evaluate risk of therapeutic failure in study participants 
during follow-up period. Change in mean haemoglobin 
level on days 0 and 28 was compared using paired t test. 
In not normally distributed data for example age; median 
Parasite density (perµl of blood)
=
WBC (8000) × Number of asexual parasites counted
Number of WBC counted (200)
value was used to measure the central tendency. Parasite 
counts were made using geometric mean. In all analysis, 
p value <0.05 was considered significant.
Ethical consideration
The study was reviewed and approved by the Ethical 
Review Committee of Jimma University, College of Public 
Health and Medical Sciences. Permission was obtained 
from Hadiya Zone Health Office, Hossana Town Admin-
istration Health Office and Hossana Health Centre. The 
purpose of the study was explained and written informed 
consent was obtained from each participant and parents 
or guardians of children.
Data quality control
Data collectors were trained by diagnostic senior experts 
from the regional referral laboratory, including the prin-
cipal investigator before the actual work. Competency 
of the data collectors was assessed and selected for the 
study. Standard operating procedures were strictly fol-
lowed. Quality of reagents and equipment was checked 
each day the diagnosis of the patient sample. All P. vivax-
positive slides on day of admission, all slides on day of 
recurrence and 5  % of negative slides were picked ran-
domly from slides prepared during follow-up and were 
re-examined blind by experts from the regional referral 
laboratory.
Results
Of a total of 1693 patients screened for malaria at Hos-
sana Health Care Centre, 1,412 were negative and 281 
were positive for malaria. Among all positive patients, 
182 were P. falciparum, 92 P. vivax and seven were 
mixed infection. From 92 P. vivax-positive patients, 
63 who fulfilled the inclusion criteria were recruited. 
Twenty-nine patients were excluded from the study 
before enrolment as they did not fulfil the inclusion 
criteria, and of these, 13 were excluded due to long dis-
tance from the health centre, seven were pregnant, six 
had prior anti-malarial intake and three refused con-
sent. From the 63 study participants, three patients 
were excluded from the study: one participant vomited 
twice during the third dose of CQ at day 2, the second 
participant was found infected by P. falciparum asexual 
stage on day 14, and the third patient was lost to follow-
up on day 14; the remaining 60 participants completed 
the 28-day follow-up (Fig. 2).
Among the recruited study participants, males were 
higher in proportion compared to females, (35 and 25, 
respectively). The median age of study participants was 
23 (range 4–59) (Table  1). Among the study partici-
pants, 32 (53.3 %) had a history of fever and 28 (46.7 %) 
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had fever at the time of enrolment. The duration of ill-
ness of the patients before enrolment was 3.05  ±  1.41 
(mean ± SD) days. The geometric mean of parasite at day 
0 was 3472.1 parasites/μl.
Based on therapeutic failure risk calculated by 
the Kaplan–Meier survival analysis, the number of 
patients at risk on day 0 was 63, but this was attributed 
to only two patients with treatment failure for 28-day 
study. Among the 60 patients, 100  % parasite clear-
ance was observed by day 21. However, in two patients 
(3.3  %) CQ treatment failure was observed during 
the follow-up period. This was observed in 10  and 
14  years old children on days 28 and 21, respectively. 
This places the risk of CQ failure until day 28 at 3.3 % 
(Table 2).
Fig. 2 Flow chart of patients’ enrolment and follow up for CQ therapeutic efficacy study at Hossana Health Care Centre Southern Ethiopia from 




























Geometric mean of parasites
Fig. 3 Parasite clearance following CQ treatment of Plasmodium vivax 
infected malaria patients at Hossana Health Care Centre Southern 
Ethiopia from April to June, 2014
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Parasite and fever clearance
Parasitaemia clearance time was 72  h for all patients 
involved in the 28-day follow up in  vivo study. At day 0 
before drug administration, the geometric mean of para-
sitaemia of the study participants was 3708 parasites/μl of 
blood (maximum 10,720 parasites/μl, minimum 1600 par-
asites/μl). The mean body temperature (in   °C) from day 
of recruitment (day 0) was 37.7, 37.26, 37.0, 36.8, 36.57, 
36.37, 36.10, and 35.99 °C for days 0, 1, 2, 3, 7, 14, and 28, 
respectively. Thus, mean body temperature of the study 
participants at the time of enrolment was 37.7  °C (mini-
mum 36.5 °C, maximum 39.1 °C). Among the study par-
ticipants, 32 (53.3 %) had a history of fever and 28 (46.7 %) 
had fever at the day of enrolment. All study participants 
cleared fever (mean body temperature on day 2 was 
37.0 °C) following parasitaemia clearance (Figs. 3 and 4).
Efficacy outcomes
The mean parasitaemia was 3708.15 parasites/µl of blood 
while the mean haemoglobin was 11.5  mg/dl on day of 
recruitment. Following CQ treatment, parasitaemia and 
fever of study participants were cleared and the mean 
haemoglobin concentration was improved (13.4  mg/dl). 
In this study, there were no early treatment failure and 
late clinical failures but two (3.3 %) LPFs were observed 
at the end of the study (on days 21 and 28). The ACPR 
after the 28-day follow-up was 58 (96.7 %).
Haemoglobin recovery
On day of enrolment, 30 (50  %) patients were found to 
have mild anaemia: one patient was found to have mod-
erate anaemia, no patients had severe anaemia and 29 
(48.3  %) were non-anaemic (haemoglobin value  ≥12  g/
dl). On the other hand, a significant (p = 0.01) increase 
was observed in the haemoglobin level between the 
baseline and day 28. Among the study participants with 
ACPR, 52 (86.7 %) were non-anaemic and eight (13.3 %) 
had mild anaemia. The mean haemoglobin concentra-
tion of study participants at day of enrolment was 11.5 g/
dl (ranging from 9.9 to 13.2 g/dl) and 13.4 g/dl (ranging 
from 10 to 14 g/dl) on day 28 (Table 3).
Table 1 Socio-demographic characteristics of  patients 
enrolled in  the in  vivo therapeutic efficacy study of  CQ 
for Plasmodium vivax malaria at Hossana Health Care Cen-
tre Southern Ethiopia from April to June 2014





 Male 35 (58.3)
 Female 25 (41.7)
Ethnicity
 Hadiya 40 (66.7)
 Kembata 11 (18.3)
 Gurage 7 (11.7)
 Silte 2 (3.3)
Occupation
 Government employee 2 (3.3)
 Unemployed 3 (5.0)
 Student 27 (45.0)
 House wife 15 (25.0)
 Farmer 8 (13.8)
 Daily laborer 4 (6.7)
 Others 1 (1.7)
Marital status
 Single 28 (46.7)
 Married 31 (51.7)
 Widowed 1
Table 2 Kaplan–Meier survival estimate of  risk of  thera-
peutic failure of  CQ for  the treatment of  Plasmodium 
vivax, at  Hossana Health Care Centre Southern Ethiopia 
from April to June, 2014
D N TF Ex IRD FCID
Day 0 63 0 0 1.000 0
Day 1 63 0 0 1.000 0
Day 2 63 0 1 1.000 0
Day 3 62 0 0 1.000 0
Day 7 62 0 0 1.000 0
Day 14 62 0 2 1.000 0
Day 21 60 1 0 0.983 0.017
Day 28 59 1 0 0.967 0.033
Total 2 3
Fig. 4 Fever clearance following CQ treatment of Plasmodium vivax 
infected malaria patients at Hossana Health Care Centre Southern 
Ethiopia from April to June, 2014
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Discussion
CQ has been in use both for treatment and prophylaxis in 
health institutions in Ethiopia. It is the anti-malarial drug 
recommended as first-line treatment for vivax malaria by 
the Federal Ministry of Health, Ethiopia [18]. However, 
there are some alarming reports on CQR vivax malaria 
from different malaria-endemic areas of Ethiopia [5–8]. It 
is becoming a major public health problem that requires 
rapid and effective management to control the spread of 
resistance, which requires proper diagnosis of cases and 
administration of effective anti-malarial drugs [13].
The present study showed the prevalence of falciparum 
and vivax malaria at Hossana Health Care Centre, south-
ern Ethiopia. Plasmodium falciparum-infected patients 
were detected more frequently than P. vivax patients dur-
ing enrolment of study participants. Out of 282 malaria-
positive patients, 182 were P. falciparum patients, 92 had 
P. vivax infections, and seven had mixed infections. A 
report from Hossana Town health office showed that in 
previous reports P. falciparum is more prevalent than P. 
vivax, which supports this recent study.
This study, a 28-day, in  vivo, therapeutic efficacy test 
on CQ undertaken at Hossana Health Care Centre has 
demonstrated two (3.3  %) LPFs. The low level of treat-
ment failure detected in the present study was compara-
ble with previous reports from different parts of Ethiopia. 
Debrezeit 2 % [5], Serbo 3.6 % [7], However, the result of 
this study was relatively lower when compared with high 
treatment failures reported from Halaba Special Woreda 
in southern Ethiopia, 11.7 % [8].
In the current study, two patients with CQ treatment 
failure were children aged 10 and 14  years, which is a 
similar condition to cases of treatment failure observed 
by studies conducted in Debrezeit and Serbo towns in 
Ethiopia [6, 7], in India [21] and in Indonesia [11] .
Decreased parasite density on day of recurrence was 
observed in this study in one patient, unlike studies done 
elsewhere [7, 22, 23]. Based on WHO guidelines for 
therapeutic efficacy study of anti-malarials, resistance is 
classified as ETF, LCF, LPF, or ACPR. Accordingly, this 
study revealed two patients with LPF, which is defined as 
presence of parasitaemia on any day from day 7 to 28 and 
axillary temperature  <37.5  °C, without previously meet-
ing any of the criteria of ETF or LCF [24, 25].
Anaemia is a major effect of malaria infection. During 
intra-erythrocytic development, malaria trophozoites 
digest haemoglobin. Thus, treatment with the appropri-
ate drug is expected to improve patients’ haemoglobin 
level with time [25]. In this study, significant increase 
in haemoglobin concentration (p  =  0.01) was observed 
from baseline to day 28 among patients with ACPR. In 
addition, one patient with treatment failure showed 
improvement of haemoglobin value on the day of recur-
rence. However, one patient with treatment failure had 
no haemoglobin improvement on the day of recurrence.
This study showed two (3.3 %) CQ treatment failures of 
vivax malaria at Hossana Health Care Centre, southern 
Ethiopia. However, the rate of resistance was lower com-
pared to a previous study elsewhere in Ethiopia, which 
was 13.7  % [8]. It is important to caution responsible 
authorities to extend efforts to monitor drug resistance 
and treatment failure problems in all malaria-endemic 
parts of the country. According to WHO first-line treat-
ment of malaria should be changed if the total failure rate 
exceeds 10 % [13]. It is important to survey CQ treatment 
failures and intervene before the level is reached that pre-
sents a public health problem.
Conclusions
The three-dose regimen of CQ showed therapeutic effi-
cacy (96.7  %) in the treatment of uncomplicated vivax 
malaria among study patients at Hossana Health Care 
Centre, southern Ethiopia. A 3.3 % CQ treatment failure 
detected in this study is LTF. Rapid clearance of fever and 
asexual parasitaemia was observed after CQ treatment 
of uncomplicated vivax malaria. Improvement in mean 
haemoglobin level was achieved following CQ treat-
ment from day 0 to 28. Regular monitoring of the pattern 
of resistance to CQ is needed in vivax malaria-endemic 
areas of the country, and measures be taken rapidly and 
effectively to control the spread of resistance. Proper 
instruction and utilization of CQ should be exercised in 
Table 3 Recovery of haemoglobin concentration observed in Plasmodium vivax infected study participants following CQ 
treatment at Hossana Health Centre, Southern Ethiopia from April to June 2014
Hb Age in years (D0) Total Age in years (D28) Total
1–4 5–14 >15 1–4 5–14 >15
Mild 0 9 (30 %) 21 (70 %) 30 (50 %) 0 4 (50 %) 4 (50 %) 8 (13.3 %)
Moderate 0 1 (1.6) 0 1 0 0 0 0
Sever 0 0 0 0 0 0 0 0
Non anemia 1 (3.4 %) 6 (20.7 %) 22 (75.9 %) 29 (48.3 %) 1 (1.9 %) 12 (23.1 %) 39 (75 %) 52 (86.7 %)
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order to avoid resistance. The prevalence of falciparum 
and vivax malaria observed in the study area requires 
strong malaria intervention measures.
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